Abstract:Endoscopic eradication therapy (EET) has revolutionized the management of Barrett's esophagus (BE)-related neoplasia (patients with early esophageal adenocarcinoma [EAC], high grade dysplasia [HGD], and select cases with low grade dysplasia), reducing the morbidity and mortality related to esophagectomy and preventing EAC-related mortality [1] [2] [3]. The basic principles of EET include endoscopic resection (ER) using endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for any visible lesion (technique of ER ideally based on lesion characteristics), followed by ablation of the remaining BE epithelium to reduce the risk of metachronous neoplasia. The goal of EET should be complete eradication of intestinal metaplasia and complete eradication of neoplasia, followed by enrollment in endoscopic surveillance programs for early detection of BE-related neoplasia recurrence. ER plays a pivotal role in both the management of patients with BE-related neoplasia and the overall success of any EET program. ER specimens routinely undergo histopathological assessment for overall highest grade of neoplasia, depth of neoplastic invasion, tumor differentiation, lymphovascular invasion, and tumor/dysplasia involvement of lateral and vertical margins. It is expected that the number of patients with a tumor-positive vertical margin (R1v) will increase given the expanding indications of EET and increased overall uptake of this management strategy for this patient population. While current guidelines recommend consideration of adjunct surgery in patients with R1v, this recommendation is based on minimal data describing outcomes and risk of residual neoplasia after R1v. Should all patients with R1v undergo esophagectomy? What is the risk of residual neoplasia in patients with R1v on follow-up endoscopy or surgical specimens after esophagectomy? "This blanket recommendation of esophagectomy for all patients with a positive margin may not be appropriate and will most likely result in "unnecessary esophagectomy" in a significant proportion of patients without high risk features associated with lymph node metastasis." In this issue of Endoscopy , van Tilburg et al. present their retrospective cohort study, which addressed the above knowledge gaps and evaluated outcomes in patients after ER for BE-related neoplasia with confirmed tumor-positive vertical margins (R1v), specifically addressing the proportion of patients with residual neoplasia (primary end point), defined as the presence of HGD or EAC detected during the first endoscopic follow-up [4]. Patients with R1v were identified from the nationwide Dutch Barrett Expert Center registry (n=110; EMR 73 and ESD 37). Resection specimens in patients with macroscopically successful ER (n = 101) were reassessed by experienced gastrointestinal pathologists in a blinded fashion, providing a consensus diagnosis of R1 (cancer cells unequivocally infiltrating the resection margin), R0 (absence of cancer cells in the margins), or not assessable (Rx). There are several key takeaways from this study. First, expert pathology reassessment resulted in confirmation of R1v status in 75% of patients and 25% were downstaged to R0 (9%) and Rx (16%). Second, among patients with confirmed R1v, 50% had residual neoplasia during endoscopic follow-up or in the surgical resection specimen (HGD or EAC), and residual neoplasia was less common in ESD than in EMR specimens. Third, among patients with endoscopic reassessment, 48% of patients had a visible suspicious lesion within 1 cm of the ER scar (residual neoplasia confirmed in 88% of these patients), and biopsies from a normal appearing ER scar did not detect additional neoplasia. Fourth, among patients with R1v who received endoscopic follow-up (median follow-up 37 months), 16% of patients had local recurrence. The limitations of this study, as acknowledged by the investigators, include the observational nature of the study, limited sample size of cases within each category, lack of standardization in terms of follow-up and management plans, and generalizability of the results to nonexpert centers. Several studies have demonstrated the interobserver variability among pathologists in the diagnosis of BE-related neoplasia [5]. In addition to the interobserver variability for the diagnosis of neoplasia, this study also highlights the variability among pathologists in the assessment of ER margins, providing credence to our current guideline recommendations that suggest expert pathology review in patients with BE-related neoplasia being considered for or undergoing EET [1] [3]. The pathologists identified several issues during assessment of ER specimens that precluded optimal histologic assessment, including tangential cutting, suboptimal embedding, curl -Abstract Truncated-

527. SURGERY FOLLOWING ENDOSCOPIC RESECTION OF EARLY OESOPHAGO-GASTRIC CANCER AT ONE LARGE TERTIARY UNIT: A RETROSPECTIVE AUDIT

471. MANAGEMENT OF EARLY ESOPHAGEAL CANCER - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Outcomes of esophagectomy after noncurative endoscopic resection of early esophageal cancer

Comparison of the Clinical and Prognosis Risk Factors Between Endoscopic Resection and Radical Gastrectomy for Early-Stage Gastric Cancer

Outcomes of endoscopic resection for high-grade dysplasia and esophageal cancer

547. DISEASE SPECIFIC MORTALITY OF EARLY-STAGE ESOPHAGEAL NEOPLASIA IN BARRETT’S ESOPHAGUS TREATED WITH ENDOSCOPIC THERAPY

The Efficacy of Additional Surgical Resection after Endoscopic Resection in Pt1b Esophageal Squamous Cell Carcinoma: A Multi-Institutional Retrospective Study in China

A129 OUTCOMES FOLLOWING ENDOSCOPIC SUBMUCOSAL DISSECTION OF SUPERFICIAL GASTROINTESTINAL TRACT NEOPLASTIC LESIONS FROM A TERTIARY-CARE ACADEMIC CENTRE

Comparative Analysis of Esophagectomy after Endoscopic Resection in Early Stage Esophageal Cancer

A retrospective study of endoscopic resection for 368 patients with early esophageal squamous cell carcinoma or precancerous lesions

Perioperative outcomes in patients who undergo neoadjuvant chemoradiotherapy versus chemotherapy versus up‐front surgery in patients with oesophageal cancer

ERAS following Gastrectomy for Octo- and Nonagenarians: A Single-Center Retrospective Analysis

Prospective assessment of adenocarcinoma of esophagogastric junction (AEG) following radical resection: Real-world insights from the CLAEG study.

Prevalence and Risk Factors for Malignant Nodal Involvement in Early esophago-gastric Adenocarcinoma: Results from the Multicenter Retrospective Congress Study (endosCopic resectiON, esophaGectomy or Gastrectomy For Early Esophagogastric Cancers)

Transition from esophagectomy to endoscopic therapy for early esophageal cancer

Approach to patients with positive vertical margins after endoscopic resection of Barrett's neoplasia

Survival after esophagectomy for metastatic esophageal cancer: Should surgery’s role be reconsidered?

Short-term outcomes of enhanced recovery after surgery protocol in minimally invasive oesophagectomy: A prospective study

Organ Preservation after Endoscopic Resection of Early Esophageal Cancer with a High Risk of Lymph Node Involvement

305 RISK OF GENERALIZATON IN PATIENTS WITH HIGH-RISK EARLY ESOPHAGEAL CANCER: RETROSPECTIVE ANALYSIS OF PROSPECTIVELY COLLECTED DATA INCLUDING LYMPH-NODE MICROMETASTASES ASSESSMENT

Prospective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer